$MYO
MYOMO, INC.

2019 Q1 Form 10-Q Financial Statement

#000156459019019136 Filed on May 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $830.1K $313.2K
YoY Change 165.05% 44.84%
Cost Of Revenue $176.2K $108.1K
YoY Change 63.02% 37.56%
Gross Profit $653.9K $205.1K
YoY Change 218.81% 48.99%
Gross Profit Margin 78.77% 65.49%
Selling, General & Admin $2.801M $2.236M
YoY Change 25.31% 95.34%
% of Gross Profit 428.43% 1090.03%
Research & Development $535.3K $372.4K
YoY Change 43.75% 4.34%
% of Gross Profit 81.86% 181.55%
Depreciation & Amortization $21.63K $14.60K
YoY Change 48.14% 573.08%
% of Gross Profit 3.31% 7.12%
Operating Expenses $3.337M $2.608M
YoY Change 27.94% 73.71%
Operating Profit -$2.683M -$2.403M
YoY Change 11.65% 76.21%
Interest Expense $42.77K $42.19K
YoY Change 1.37% -125.13%
% of Operating Profit
Other Income/Expense, Net $84.74K $57.50K
YoY Change 47.38% -129.83%
Pretax Income -$2.598M -$2.350M
YoY Change 10.56% 50.64%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.598M -$2.345M
YoY Change 10.77% 50.69%
Net Earnings / Revenue -312.99% -748.9%
Basic Earnings Per Share
Diluted Earnings Per Share -$5.216M -$197.5K
COMMON SHARES
Basic Shares Outstanding 17.08M 12.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.234M $14.12M
YoY Change -34.61%
Cash & Equivalents $9.309M $14.12M
Short-Term Investments
Other Short-Term Assets $784.7K $370.0K
YoY Change 112.09%
Inventory $171.5K $237.9K
Prepaid Expenses
Receivables $399.9K $151.4K
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.72M $14.88M
YoY Change -27.96%
LONG-TERM ASSETS
Property, Plant & Equipment $173.1K $155.3K
YoY Change 11.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $207.0K $50.00K
YoY Change 313.96%
Total Long-Term Assets $380.1K $207.3K
YoY Change 83.32%
TOTAL ASSETS
Total Short-Term Assets $10.72M $14.88M
Total Long-Term Assets $380.1K $207.3K
Total Assets $11.10M $15.09M
YoY Change -26.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $525.6K $240.0K
YoY Change 119.01%
Accrued Expenses $784.8K $710.0K
YoY Change 10.54%
Deferred Revenue $84.12K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.578M $1.117M
YoY Change 41.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $50.00K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $50.00K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.578M $1.117M
Total Long-Term Liabilities $0.00 $50.00K
Total Liabilities $1.578M $1.162M
YoY Change 35.82%
SHAREHOLDERS EQUITY
Retained Earnings -$45.41M -$37.32M
YoY Change 21.69%
Common Stock $57.54M $1.240K
YoY Change 4639978.95%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K $6.464K
YoY Change 0.0%
Treasury Stock Shares 808.0 shares
Shareholders Equity $9.436M $13.92M
YoY Change
Total Liabilities & Shareholders Equity $11.10M $15.09M
YoY Change -26.43%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$2.598M -$2.345M
YoY Change 10.77% 50.69%
Depreciation, Depletion And Amortization $21.63K $14.60K
YoY Change 48.14% 573.08%
Cash From Operating Activities -$3.120M -$2.265M
YoY Change 37.72% 94.99%
INVESTING ACTIVITIES
Capital Expenditures $5.404K $64.92K
YoY Change -91.68% 1426.9%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.404K -$64.92K
YoY Change -91.68% 1426.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.600M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.818M 3.487M
YoY Change 66.83% 96.72%
NET CHANGE
Cash From Operating Activities -3.120M -2.265M
Cash From Investing Activities -5.404K -64.92K
Cash From Financing Activities 5.818M 3.487M
Net Change In Cash 2.693M 1.157M
YoY Change 132.73% 90.71%
FREE CASH FLOW
Cash From Operating Activities -$3.120M -$2.265M
Capital Expenditures $5.404K $64.92K
Free Cash Flow -$3.125M -$2.330M
YoY Change 34.12% 99.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
372359
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
144582
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
187513
CY2018Q4 us-gaap Assets
Assets
8281572
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1743427
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3661
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1990
CY2019Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
84117
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
106609
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1578313
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1855687
CY2018Q4 us-gaap Liabilities
Liabilities
1855687
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1245
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57536979
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48011033
CY2019Q1 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9521192
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11099505
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
830066
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
313179
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
176187
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
108080
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2801420
CY2019Q1 us-gaap Gross Profit
GrossProfit
653879
CY2018Q1 us-gaap Gross Profit
GrossProfit
205099
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
535254
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33912
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2235637
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3336674
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2607996
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2682795
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2402897
CY2019Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
41970
CY2018Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
15307
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
42765
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
42188
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
84735
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
57495
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2598060
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2345402
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14941518
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11899456
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-123447
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5648928
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
144556
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
11961
CY2019Q1 myo Fair Value Of Warrants Issued Recorded As Derivative Liability
FairValueOfWarrantsIssuedRecordedAsDerivativeLiability
196236
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
207605
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
12445778
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-63149
CY2018Q1 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
3550490
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
336355
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
13924072
CY2018Q1 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
17570
CY2019Q1 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
45459
CY2018Q1 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
CY2019Q1 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
710572
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-2598060
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-2345402
CY2019Q1 us-gaap Depreciation
Depreciation
21627
CY2018Q1 us-gaap Depreciation
Depreciation
14599
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
207605
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
336355
CY2019Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
16275
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
-645
CY2019Q1 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
41970
CY2018Q1 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
15307
CY2019Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-320
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-145594
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
131871
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
63923
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
128256
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15182
CY2019Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-432998
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-327390
CY2019Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
23850
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-24423
CY2019Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-22492
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5404
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3550490
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3119882
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2265360
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64924
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5404
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64924
CY2019Q1 myo Proceeds From Payments For Issuance Costs
ProceedsFromPaymentsForIssuanceCosts
12606
CY2019Q1 myo Proceeds From Payments Related To Tax Withholding For Share Based Compensation
ProceedsFromPaymentsRelatedToTaxWithholdingForShareBasedCompensation
156517
CY2018Q1 myo Proceeds From Payments Related To Tax Withholding For Share Based Compensation
ProceedsFromPaymentsRelatedToTaxWithholdingForShareBasedCompensation
-63149
CY2019Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5648928
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5818051
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3487341
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2692765
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1157057
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6615794
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13011373
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9308559
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14168430
CY2019Q1 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
2108
CY2018Q1 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
27944
CY2019Q1 myo Issuance Of Warrants Recorded As Derivative Liability
IssuanceOfWarrantsRecordedAsDerivativeLiability
196236
CY2019Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8212; Description of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myomo Inc. (&#8220;Myomo&#8221; or the Company&#8221;) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro &#174; myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class&#160;II medical device. The Company sells its products to orthotics and prosthetics (O&amp;P) providers, the Veterans Health Administration, rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, utilizing the clinical services of O&amp;P providers for which they are paid a fee. The Company was incorporated in the State of Delaware on September&#160;1, 2004 and is headquartered in Cambridge, Massachusetts.</p>
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company&#8217;s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving and consigned inventory.</p>
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
207605
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.14
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5600000
CY2019Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
525624
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
426727
CY2019Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
470974
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1027757
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
23750
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
290081
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
288943
CY2019Q1 us-gaap Inventory Net
InventoryNet
171514
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
656464
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45412973
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5856642
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5714268
CY2019Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
296727
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
146640
CY2019Q1 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
135635
CY2018Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
135635
CY2019Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
28550
CY2018Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
48874
CY2019Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
460912
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
331149
CY2019Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
24000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
24000
CY2019Q1 myo Inventory Reserves Under Consignment
InventoryReservesUnderConsignment
135635
CY2018Q4 myo Inventory Reserves Under Consignment
InventoryReservesUnderConsignment
51000
CY2019Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8730149
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3661
CY2019Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
196236
CY2019Q1 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-41970
CY2019Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
157927
CY2019Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2018Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
74000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
206500
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6208
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.79
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
336355
CY2019Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
26000
CY2018Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
75000
CY2019Q1 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
26000
CY2018Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
110000
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
127000
CY2019Q1 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
84000
CY2018Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
54000

Files In Submission

Name View Source Status
0001564590-19-019136-index-headers.html Edgar Link pending
0001564590-19-019136-index.html Edgar Link pending
0001564590-19-019136.txt Edgar Link pending
0001564590-19-019136-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
myo-10q_20190331.htm Edgar Link pending
myo-20190331.xml Edgar Link completed
myo-20190331.xsd Edgar Link pending
myo-20190331_cal.xml Edgar Link unprocessable
myo-20190331_def.xml Edgar Link unprocessable
myo-20190331_lab.xml Edgar Link unprocessable
myo-20190331_pre.xml Edgar Link unprocessable
myo-ex311_6.htm Edgar Link pending
myo-ex312_9.htm Edgar Link pending
myo-ex321_7.htm Edgar Link pending
myo-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending